Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$110.02 -0.9%	$105.14	$76.53 ▼ $131.49	$26.45B	1.29	942,215 shs	616,421 shs
INSM Insmed	$102.56 -1.5%	$86.93	$60.40 ▼ $106.83	$19.46B	0.9	2.29 million shs	1.43 million shs
ONC BeOne Medicines	$294.55 +1.4%	$250.96	$152.81 ▼ $300.00	$32.28B	0.28	388,965 shs	893,521 shs
ROIV Roivant Sciences	$11.44 -1.8%	$11.16	$8.73 ▼ $13.06	$7.78B	1.15	5.72 million shs	4.93 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	0.00%	-2.54%	+3.28%	+8.06%	+28.74%
INSM Insmed	0.00%	+4.46%	-0.12%	+47.55%	+35.00%
ONC BeOne Medicines	0.00%	+17.68%	+19.21%	+28.50%	+29,454,999,900.00%
ROIV Roivant Sciences	0.00%	+0.70%	-0.09%	+13.94%	+4.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	1.4508 of 5 stars	3.4	2.0	0.0	1.3	0.8	0.0
INSM Insmed	3.9639 of 5 stars	2.5	4.0	4.3	2.8	1.7	0.6
ONC BeOne Medicines	2.6311 of 5 stars	3.5	0.0	0.0	3.1	1.7	0.6
ROIV Roivant Sciences	2.7333 of 5 stars	3.6	3.0	0.0	2.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.83	Moderate Buy	$136.58	24.14% Upside
INSM Insmed	3.00	Buy	$108.47	5.76% Upside
ONC BeOne Medicines	3.00	Buy	$327.56	11.21% Upside
ROIV Roivant Sciences	3.25	Buy	$16.50	44.23% Upside

Current Analyst Ratings Breakdown

Latest ROIV, ONC, BNTX, and INSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$102.00 ➝ $108.00
7/17/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$321.00 ➝ $345.00
7/16/2025	BNTX BioNTech	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $126.00
7/16/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$311.00 ➝ $349.00
7/10/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$132.00 ➝ $133.00
7/10/2025	ROIV Roivant Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$19.00
7/8/2025	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $111.00
6/27/2025	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$313.00 ➝ $330.00
6/27/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$317.00 ➝ $321.00
6/27/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$311.00
6/25/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$138.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.98B	8.88	N/A	N/A	$87.61 per share	1.26
INSM Insmed	$363.71M	53.49	N/A	N/A	$1.60 per share	64.10
ONC BeOne Medicines	$3.81B	8.47	N/A	N/A	$34.10 per share	8.64
ROIV Roivant Sciences	$29.05M	267.71	N/A	N/A	$7.45 per share	1.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$719.92M	-$3.40	N/A	N/A	N/A	-27.37%	-3.94%	-3.41%	8/4/2025 (Estimated)
INSM Insmed	-$913.77M	-$5.95	N/A	N/A	N/A	-265.93%	-446.98%	-52.70%	8/6/2025 (Estimated)
ONC BeOne Medicines	-$644.79M	-$3.72	N/A	414.86	N/A	-9.40%	-7.55%	-4.42%	8/6/2025 (Confirmed)
ROIV Roivant Sciences	-$171.98M	-$0.25	N/A	N/A	N/A	-225.71%	-14.76%	-13.69%	8/6/2025 (Estimated)

Latest ROIV, ONC, BNTX, and INSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	INSM Insmed	-$1.31	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q1 2026	ROIV Roivant Sciences	-$0.23	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	BNTX BioNTech	-$1.38	N/A	N/A	N/A	$161.26 million	N/A
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/8/2025	Q1 2025	INSM Insmed	-$1.36	-$1.42	-$0.06	-$1.42	$91.63 million	$92.82 million
5/7/2025	Q1 2025	ONC BeOne Medicines	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	10.18	10.02
INSM Insmed	11.38	5.86	5.44
ONC BeOne Medicines	0.05	1.96	1.71
ROIV Roivant Sciences	N/A	33.47	33.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
INSM Insmed	N/A
ONC BeOne Medicines	48.55%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
INSM Insmed	3.00%
ONC BeOne Medicines	6.62%
ROIV Roivant Sciences	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	6,772	240.39 million	194.24 million	Optionable
INSM Insmed	1,271	189.71 million	184.02 million	Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A
ROIV Roivant Sciences	860	679.81 million	626.10 million	Optionable

ROIV, ONC, BNTX, and INSM Headlines

Recent News About These Companies

Mutual of America Capital Management LLC Sells 142,139 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

July 20 at 3:51 AM | marketbeat.com

CenterBook Partners LP Buys New Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 16, 2025 | marketbeat.com

Bank of New York Mellon Corp Has $40.36 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 15, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Stock Rating Upgraded by The Goldman Sachs Group

July 13, 2025 | americanbankingnews.com

Roivant Sciences Ltd. (ROIV) - Yahoo Finance

July 10, 2025 | finance.yahoo.com

Roivant Sciences (NASDAQ:ROIV) Earns Buy Rating from Analysts at The Goldman Sachs Group

July 10, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Sees Unusually-High Trading Volume - Still a Buy?

July 9, 2025 | marketbeat.com

DAVENPORT & Co LLC Reduces Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 9, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Stock Position Decreased by New York State Teachers Retirement System

July 9, 2025 | marketbeat.com

'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 million in five months

June 28, 2025 | msn.com

Roivant Sciences’ president Venker sells $1.15 million in shares

June 26, 2025 | investing.com

Investors Buy Large Volume of Roivant Sciences Call Options (NASDAQ:ROIV)

June 26, 2025 | marketbeat.com

Penn Davis Mcfarland Inc. Has $17.23 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 25, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,145,000.00 in Stock

June 25, 2025 | insidertrades.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 Shares

June 24, 2025 | marketbeat.com

Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat

June 24, 2025 | msn.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells 565,266 Shares of Stock

June 24, 2025 | insidertrades.com

Roivant Sciences (ROIV) : Ramaswamy vend des actions pour 13 millions

June 23, 2025 | fr.investing.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $6,472,295.70 in Stock

June 23, 2025 | marketbeat.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells 577,007 Shares of Stock

June 23, 2025 | marketbeat.com

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

June 16, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

D-Wave Is Rising Again Despite Dilution—What’s the Deal?
By Nathan Reiff | July 7, 2025
View D-Wave Is Rising Again Despite Dilution—What’s the Deal?
Palantir Gets Price Hike From Wedbush Amid High Valuation
By Chris Markoch | July 15, 2025
View Palantir Gets Price Hike From Wedbush Amid High Valuation
These 3 Dividend Stocks Are Not Concerned With Tariff Noise
By Thomas Hughes | July 11, 2025
View These 3 Dividend Stocks Are Not Concerned With Tariff Noise
IGM ETF: Expand Tech Exposure With Top AI Leaders
By Jeffrey Neal Johnson | July 1, 2025
View IGM ETF: Expand Tech Exposure With Top AI Leaders
MarketBeat Week in Review – 07/07 - 07/11
By MarketBeat Staff | July 12, 2025
View MarketBeat Week in Review – 07/07 - 07/11

ROIV, ONC, BNTX, and INSM Company Descriptions

BioNTech NASDAQ:BNTX

$110.02 -1.02 (-0.92%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$110.32 +0.30 (+0.27%)

As of 06:30 AM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Insmed NASDAQ:INSM

$102.56 -1.61 (-1.55%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$102.74 +0.17 (+0.17%)

As of 04:48 AM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

BeOne Medicines NASDAQ:ONC

$294.55 +4.20 (+1.45%)

As of 07/18/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Roivant Sciences NASDAQ:ROIV

$11.44 -0.21 (-1.80%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$11.37 -0.07 (-0.65%)

As of 04:54 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time